Introduction Surgery is the standard treatment for early stage non–small-cell lung cancer
(NSCLC). For medically inoperable patients, stereotactic ablative radiotherapy (SABR) has …

Objectives Comparative studies of survival between stereotactic body radiation therapy
(SBRT) and surgery have been limited by lack of comparisons of recurrence patterns …

Background The clinical stage of non-small cell lung cancer (NSCLC) determines the initial
treatment, whereas the pathologic stage best determines prognosis and the need for …

Purpose: Technologic developments have made radiation therapy (RT) more effective and
have introduced new treatment options, such as stereotactic ablative radiation therapy …

Objectives Guideline-specified curative therapies for a clinical stage I non-small cell lung
cancer (NSCLC) are either lobectomy or Stereotactic Ablative Radiotherapy (SABR). As …

BACKGROUND: Approximately two-thirds of patients with early-stage non-small-cell lung
cancer (NSCLC) in The Netherlands currently undergo surgical resection. As an increasing …

Background Stereotactic ablative body radiation therapy (SBRT) has evolved as the
standard treatment for patients with inoperable stage I non–small-cell lung cancer (NSCLC) …

Whether stereotactic ablative radiotherapy (SABR) is comparable to surgery in treating stage
I non-small-cell lung cancer (NSCLC) is unknown. Therefore, we conducted this meta …

Surgery is the gold therapeutic standard for patients affected with stage I non-small cell lung
cancer. Stereotactic ablative radiotherapy is currently considered the preferred treatment …

Background: Surgical resection is the treatment of first choice for patients with stage I-II non-
small cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been …